

U.S. Department of Veterans Affairs

Veterans Health Administration PBM Academic Detailing Service

A QUICK REFERENCE GUIDE (2017)

Pain

Transforming the Treatment of Pain

VA PBM Academic Detailing Service Real Provider Resources

Real Patient Results

Your Partner in Enhancing Veteran Health Outcomes

VA PBM Academic Detailing Service Email Group PharmacyAcademicDetailingProgram@va.gov

VA PBM Academic Detailing Service SharePoint Site https://vaww.portal2.va.gov/sites/ad

VA PBM Academic Detailing Public Website http://www.pbm.va.gov/PBM/academicdetailingservicehome.asp

Table of Contents

Abbreviations 1
Stepwise Approach to Acute Pain Management 2
Stepwise Approach to Chronic Pain Management 3
Topical Agents for Acute and Chronic Musculoskeletal Pain and Neuropathic Pain4–8
Non-Opioid Agents for Acute and Chronic Musculoskeletal Pain
Antidepressants and Anticonvulsants for Musculoskeletal and Neuropathic Pain 11-12
Opioids for Acute Pain 13
Calculating Morphine Milligram Equivalent Daily Dose (MEDD) 14
Considerations When Prescribing Methadone 15
Methadone Dosing Strategies 16–17

TOC (continued)

Monitoring Patients on Chronic Opioid Therapy	
Assess Baseline Pain and Function - PEG Scale	
Risk Mitigation Strategies for Patients on Chronic Opioids	20–21
Urine Drug Testing Methods	22–23
Urine Drug Testing (UDT) Federal Work Place Cut Off Values	24–26
Summary of Agents Potentially Contributing to False Positives	27–28
Interpreting Urine Drug Testing	29–33
Common Adverse Effects for Opioid Analgesics and Suggested Management	
Less Common Adverse Effects	35–36
Example of Opioid Tapers	37
Follow Up with the Veteran During the Taper	
Benzodiazepine Dosage Equivalents and Taper Schedules	
References	40

Abbreviations

6-MAM = 6-monoacetylmorpine APAP = acetaminophen

BEG = benzoylecognine

BP = blood pressure

CABG = coronary artery bypass graft

CBD = cannabidiol

CrCl = creatinine clearance

EC = enteric coated

EDDP = 2-ethylidene-1,5dimethyl-3,3-diphenylpyrrolidine EtG = ethyl glucuronide EtS = ethyl sulfate GCMS = gas chromatographymass spectrometry **GI** = gastrointestinal

HR = hour(s)

IR = immediate release

MDA = 3,4-methylenedioxyamphetamine

MDEA = 3,4-methylenedioxy-Nethyl-amphetamine

MDMA = 3,4-methylenedioxymethamphetamine

MEDD = morphine equivalent dose mL = milliliter(s) NSAID = nonsteroidal antiinflammatory drug ng = nanogram(s) OEND = opioid overdose education and naloxone distribution

PDMP = prescription drug monitoring program PPI = proton pump inhibitor THC = tetrahydrocannabinol THCA = delta-9tetrahydrocannabinol-9carboxylic acid UTS = urine toxicology screening UDT = urine drug testing XR = extended release

Stepwise Approach to Acute Pain Management¹⁻²



Tips for Treating Acute Pain

- Reserve opioids for pain that is not expected or does not respond to Step 1 and Step 2 treatments
- Prescribe for less than 3 to 5 days then evaluate the need to continue therapy
- Use short acting opioids only

Stepwise Approach to Chronic Pain Management

Self-management and treating comorbidities Non-pharmacologic therapy Step Non-opioid pharmacotherapy 4 Intensive Interdisciplinary Pain Rehabilitation Intermittent use of opioids for limited conditions Self-management and treating comorbidities Step Non-pharmacologic therapy 3 Non-opioid pharmacotherapy Self-management and Step treating comorbidities Non-pharmacologic therapy Step Self-management and optimized treatment of comorbidities

Topical Agents for Acute and Chronic Musculoskeletal Pain and Neuropathic Pain³

Generic Name	Type of Pain	Usual Adult Dose	Maximum Dose	Comments
Diclofenac Gel 1%	Musculoskeletal	Upper extremity (hand, wrist, or elbow): 2 grams applied 4 times daily Lower extremity (foot, knee, ankle): 4 grams applied 4 times daily Do not use with oral NSAID	Upper extremity: do not exceed 8 grams a day to any single joint. Lower extremity: do not exceed 16 grams a day to any single joint.	Not evaluated for use on the spine, hip or shoulder. Risk of gastrointestinal bleeding is lower than oral diclofenac, but can occur. Dosing card provided to help measure grams for application. Contraindicated for treating preoperative pain before CABG and should be avoided for 14 days after CABG surgery.

Generic Name	Type of Pain	Usual Adult Dose	Maximum Dose	Comments
Diclofenac Patch 1.3%	Musculoskeletal	Patch: 1 patch to most painful area twice a day	Same as usual dose	Patch: Approved for treatment of acute pain due
Diclofenac Topical Solution 1.5%, 2%		1.5% solution: 40 drops to each affected knee 4		to minor strains, sprains and contusions.
tir 29 (2 ea tir Do or		times a day		Solution: FDA approved for osteoarthritis of the knee.
	(2 pump actuations) to each affected knee 2 times a day		Risk of gastrointestinal bleeding is lower than oral diclofenac, but can	
		Do not use with oral NSAID		occur. Contraindicated for treating preoperative pain before CABG and should be avoided for 14 days after CABG surgery.

Generic Name	Type of Pain	Usual Adult Dose	Maximum Dose	Comments
Lidocaine Patch 5%	Musculoskeletal and neuropathic	1–3 patches applied once for up to 12 hours within a 24 hour period	3 patches every 12 hours	May cut patches to fit painful area. Can consider using patches every 12 hours if pain responds to patch. Systemic absorption and toxicity can occur if used on irritated or broken skin.

Generic Name	Type of Pain	Usual Adult Dose	Maximum Dose	Comments
Methyl Salicylate/ Menthol Cream	Musculoskeletal	Low concentration 10–15%: Apply to affected area up to 3 to 4 times a day High concentration 16–30%: Apply to affected area up to 3 to 4 times a day	Same as usual dose	Do not use on open wounds, avoid contact with eyes or mucous membranes, do not use with a heating pad.
Methyl Salicylate 10%/Menthol 3% Patches	Musculoskeletal	1 patch every 8 to 12 hours; up to 2 patches a day	Same as usual dose	

Generic Name	Type of Pain	Usual Adult Dose	Maximum Dose	Comments
Capsaicin Cream/ Ointment	Musculoskeletal and neuropathic	0.025%: apply thin film to affected area 2–4 times daily	0.075%: apply thin film to affected area 2–4 times daily	Wash hands after use or wear gloves to apply; do not use near eyes or mucous membranes. Requires scheduled use.

Non-Opioid Agents for Acute and Chronic Musculoskeletal Pain³

Generic Name	Usual Adult Dose	Maximum Dose	Comments	
Acetaminophen	650–1000 mg every 4–6 hours PRN	4000 mg daily in healthy patients 2000 mg daily in	No platelet (<2000 mg daily) or anti-inflammatory effect. Adjust dose in alcoholic or hepatic dicease	
		hepatic impairment		
NSAIDs				
Diclofenac EC	50–75 mg every 8–12 hours PRN	150 mg daily	Use NSAIDs with caution in	
Etodolac	200–400 mg every 6–8 hours PRN	1200 mg daily	renal/hepatic impairment,	
lbuprofen	200–400 mg every 4–6 hours PRN	800 mg per dose or 3200 mg daily	patients receiving concurrent anticoagulants or lithium.	
Meloxicam	7.5 mg once daily PRN	15 mg once daily	Consider using PPI for patients	
Naproxen	250–500 mg every 6–12 hours PRN	1250 mg a day initial dose then 1000 mg daily	at high risk for developing upper GI bleeding. Contraindicated for treating preoperative pain	
Salsalate	500–1000 mg every 8–12 hours PRN	3000 mg daily	before CABG surgery and should	
Sulindac	150–200 mg every 12 hours PRN	400 mg daily	be avoided for 14 days after CABG surgery.	

Generic Name	Usual Adult Dose	Maximum Dose	Comments
	Non-benzodiazepine	Skeletal Muscle Relaxants	
Methocarbamol	750–1500 mg every 6 hours for first 2–3 days, then use lowest effective dose, e.g., 500–1000 mg every 6–12 hours PRN	1500 mg 4 times daily	Drowsiness is common. Prescribing for a limited duration
Cyclobenzaprine	5 mg three times daily PRN	10 mg three times daily	Advise to avoid operating
Baclofen	5–10 mg three times daily PRN	20 mg four times daily	heavy machinery or driving;
Tizanidine	2–4 mg every 8 hours PRN	8 mg single dose or 24 mg daily	

Antidepressants and Anticonvulsants for Musculoskeletal and Neuropathic Pain³

Generic Name	Usual Adult Dose	Maximum Dose	Comments				
	Antidepressants						
Amitriptyline	10–150 mg at bedtime	150 mg daily	Caution in elderly and patients with cardiac				
Imipramine	10–150 mg at bedtime	150 mg daily	disease. Use no more than 75 mg at bedtime for				
Nortriptyline	10–150 mg at bedtime	150 mg daily	patients over the age of 65 years old. Amitriptyline				
Desipramine	10–150 mg at bedtime	150 mg daily	than nortriptyline or desipramine. May cause QTc prolongation, avoid if QTc >450 ms.				
Venlafaxine	IR: 75–150 mg twice daily XR: 75–225 mg daily	IR: 300 mg daily (divided) XR: 225 mg daily	Adjust dose based on renal function. Higher doses associated with increased blood pressure.				
Duloxetine	30–60 mg daily	60 mg daily	Avoid in patients with hepatic insufficiency. Avoid with CrCl <30 mL/min. Monitor BP. Higher doses for pain have not been shown to provide additional benefit.				

Generic Name	Usual Adult Dose	Maximum Dose	Comments
		Antiepileptics	
Gabapentin	300 mg at bedtime and titrate to 300–900 mg every 8–12 hours	3600 mg daily in divided doses	Adjust dose based on renal function.
Pregabalin	50–150 mg every 8–12 hours	300 mg daily in divided doses	Adjust dose based on renal function. Studied up to 600 mg/day with no additional benefit in pain reduction and an increase in adverse effects.
Carbamazepine	100–200 mg every 6–12 hours	1200 mg daily in divided doses	Avoid in patients with active liver disease. Used primarily for trigeminal neuralgia. Hepatic enzyme
Oxcarbazepine	300 mg twice daily	1200–2400 mg daily in divided doses	inhibitor of CYP2C19 and inducer of CYP3A4/5, must be cautious of drug interactions. Serious dermatologic reactions, including Stevens- Johnson syndrome and toxic epidermal necrolysis reactions have been reported. Oxycarbazepine may be better tolerated than carbamazepine.

Opioids for Acute Pain^{1–3}

Initial Dose: Opioid Naïve <table-cell-rows> Limit to a 3 to 5 day supply then reassess*</table-cell-rows>						
Opioid	Milligrams (mg)	Dose/Day	mg MEDD	Drug Prescribed	Initial Quantity (3 day supply)	
Codeine	15–30	2–3	6.75 to 13.5	Codeine 30 mg/APAP 300 mg	9 tablets	
Hydrocodone	5–10	3	15 to 30	Hydrocodone/APAP 5/500	9 to 18 tablets	
Hydromorphone IR	2	2–3	24	Hydromorphone IR 2 mg	9 tablets	
Morphine IR	7.5–15	2–3	22.5 to 45	Morphine IR 15 mg	9 tablets	
Oxycodone IR	5–10	2–3	22.5 to 45	Oxycodone IR 5 mg or Oxycodone 5 mg/APAP 325 mg	9 to 18 tablets	
Oxymorphone IR	5	2–3	45	Oxymorphone IR 5 mg	9 tablets	
Tapentadol IR	50	2–3	60	Tapentadol IR 50 mg	9 tablets	
Tramadol	25–50	2–3	N/A	Tramadol 50 mg	9 tablets	

*Supply should be limited to 3–5 days; however in some cases of severe pain, treatment may need to be longer.

Calculating Milligram Morphine Equivalent Daily Dose (MEDD)²

Opioid Agent	Conversion Factor	How to Calculate
Codeine	0.15	
Tapentadol	0.4	1. Determine the total daily dose (TDD) of all opioids.
Morphine	1	2. Convert to mg MEDD by multiplying the TDD of each
Hydrocodone	1	opioid by their conversion factor.
Oxycodone	1.5	3. Add all opioids together.
Fentanyl Transdermal (in mcg/hr)	2.4	
Oxymorphone	3	Example: Veteran taking Ovycodono SP 20 mg three times daily
Hydromorphone	4	and Hydrocodone/APAP 10/325 mg 4 tablets a day.
Methadone 1–20 mg/day 21–40 mg/day 41–60 mg/day ≥61–80 mg/day	4 8 10 12	Oxycodone 60 mg daily x $1.5 = 90$ Hydrocodone/APAP 40 mg daily x $1 = 40$ Total mg MEDD = 130

This is only an estimate and cannot account for individual variability in genetics and pharmacokinetics. Do not use the calculated MEDD when converting from one opioid to another. When converting opioids, the new opioid dose is usually substantially lower than the calculated MEDD dose (33–50% less) to avoid accidental overdose.

Considerations When Prescribing Methadone^{2,4}

Dose Titration

• Wait at least 5–7 days before increasing the dose

L

QTc Prolongation

- Avoid use if QTc is >500 ms
- Caution if QTc 450–500 ms
 - Patients with Risk of QTc Prolongation or History of >450 ms
 - Baseline ECG then repeat 2-4 weeks after starting
 - ECG after dose changes
 - ECG when methadone dose >30 mg/day and again if reaching 100 mg/day
 - Consider alternative if QTc 450–500 ms or if patient has new risk factors or signs/symptoms suggestive of arrhythmia

Patients Not Known to be at High Risk of QTc Prolongation

- Baseline ECG in past 12 months
- ECG when methadone dose >30 mg/day and again if reaching 100 mg/day
- New risk factors or signs/symptoms suggestive of arrythmia

Methadone is not a firstline treatment for chronic pain. It has unique pharmacokinetics that make it different from other opioids and should only be prescribed by an experienced provider or in consultation with a specialist.

Methadone Dosing Strategies^{4–11}

Methadone Dosing Strategies

Dosing strategies for patients receiving codeine preparations or no previous opioid:

- Gradual titration
 - Start with 2.5 mg every 8 to 12 hours; may start at a lower dose using methadone solution 1 mg/ml
 - Increase dose by 2.5 to 7.5 mg (in divided doses), no more often than every 5–7 days
 - Start low and go slow

Dosing strategies for patients taking opioids chronically:

• Determine the equianalgesic dose

Morphine (mg/day)	<30	31–99	100–299	300-499	500–999	1000–1200	>1200
Morphine: Methadone	2:1*	4:1*	8:1*	12:1*	15:1*	20:1*	Consult*

*Methadone conversions should only be performed by an experienced provider or in consultation with a specialist.

Methadone Dosing Strategies

Dosing strategies for patients taking opioids chronically (cont.):

- Rapid conversion
 - Discontinue the previous opioid
 - Start calculated methadone dose on day 1
 - Titrating strategies
 - Dose titration 2.5 mg every 8 hours after 5–7 days
 OR
 - Calculate how much opioid was used for breakthrough pain on days 5, 6 and 7 and use the average amount, convert to mg methadone and increase accordingly. Do not use methadone as needed. Opioids for breakthrough pain include oxycodone with or without acetaminophen, hydrocodone/acetaminophen, and immediate release morphine
- Stepwise conversion may be a better option with high doses
 - Dose of previous opioid is reduced by 1/3 and replaced with 1/3 of the calculated methadone dose (in 3 divided doses)
 - After several days to weeks reduce original opioid by an additional 1/3 and the methadone dose is increased by 1/3
 - After several days to weeks the remaining 1/3 of the previous opioid is discontinued and the methadone dose is increased to the initial calculated dose

*Methadone conversions should only be performed by an experienced provider or in consultation with a specialist.

Monitoring Patients on Chronic Opioid Therapy—Perform at Each Follow Up Visit^{1,2}

Assess

- Function, risks and benefits of opioid therapy
- Adverse effects
- Progress toward functional treatment goals
- · Adherence to treatment plan
- · Complications or co-occurring conditions (medical, mental health, and/or SUD)

Complete Risk Mitigation Strategies

- Urine drug testing (UDT)
- Prescription drug monitoring program (PDMP)
- · Monitoring for overdose and suicidality
- Opioid overdose education and naloxone distribution (OEND)

Discuss expectations and optimize comprehensive pain care plan

Evaluate for opioid taper

Follow up should be performed at least every 3 months if opioid dose is stable and more frequently if needed based on risk factors.

Assess Baseline Pain and Function—PEG Scale¹²

Does not interfere

Pain, enjoyment, general activity scale (PEG Scale)—scale from 0–10.

1. What number best describes your Pain on average in the past week?

 [__1 2 3 4 5 6 7 8 9 10___]

 No pain

 Bad as you can imagine

2. What number best describes how, during the past week, pain has interfered with your Enjoyment of life?

 [__1 2 3 4 5 6 7 8 9 10___]

 Does not interfere
 Completely interferes

What number best describes how, during the past week, pain has interfered with your General activity?
 [_1 2 3 4 5 6 7 8 9 10___]

Completely interferes

Risk Mitigation Strategies for Patients on Chronic Opioids^{1,2,5}

Opioid Risk	Recommended Frequency UDT	Recommended Frequency PDMP
All Patients	At least once yearly	Once a year at minimum; prescribers must follow requirements by their state of licensure.
 Higher Risk Patients Opioid doses ≥ to 90 mg MEDD Concomitant benzodiazepine use OUD 	At least every 3 months	Every prescription.
 Aberrant Behavior Lost or stolen prescriptions Taking larger than prescribed doses Frequent emergency department visits Demanding increased doses Using opioids or other controlled substances that are not prescribed 	At the time of the visit or when the Veteran presents with the aberrant behavior; address behaviors in person	At time of visit. It is important to address aberrant behaviors in person.

UDT Results—Red Flags

The following should be viewed as a **"red flag"**, requiring confirmation testing and intervention (see interpreting UDT page 29):

- Negative for opioid(s) prescribed
- Positive for prescription medications not prescribed (e.g., opioids, benzodiazepines, stimulants)
- Positive for illicit drugs (e.g., methamphetamine, cocaine or its metabolites)
- Positive for alcohol or its metabolites

If confirmatory drug test substantiates the "red flag" (e.g., positive for amphetamines) AND is:

- **Positive for prescribed opioids**: have a discussion with the patient, come up with a plan (consider a slow taper and consultation with/referral to an addiction treatment program).
- Negative for prescribed opioids: have a discussion with the patient, come up with a plan (consider consultation with/referral to an addiction treatment program; tapering of prescribed opioid not necessary if patient not taking prescribed opioid).

Urine Drug Testing Methods^{5,13–15}

Type of Test	Logistics	Pearls			
	Initial Screening Test				
Immunoassay*	InexpensiveFastWidely available	 High sensitivity, low specificity (higher potential for false positives) Opiate screen not sensitive for semisynthetic (e.g., oxycodone) or synthetic opioids (e.g., fentanyl) 			
Confirmatory Test					
Gas Chromatography-Mass Spectrometry (GCMS)**	ExpensiveTime consuming	High sensitivity, high specificityDetects medication even if			
Liquid Chromatography-Mass Spectrometry (LCMS)	Less expensive than GCMSFaster than GCMS	 concentration low Allows detection of a specific drug/metabolite 			

*Immunoassay tests have high predictive values for tetrahydrocannabinol (THC), the testing component of marijuana, and also for cocaine, but lower predictive values for opioids and amphetamines. **GMCS is considered the criterion standard for confirmatory testing.

Normal Characteristics of a Urine Sample

- Temperature within 4 minutes of voiding: 90°–100°F
- pH: 4.5-8.0
- Creatinine: >20 mg/dL
- Specific gravity: >1.003
- Nitrates: <500 mcg/dL
- Volume: ≥30 mL

Urine Drug Testing Specimen Validity

- · Urine samples that are adulterated, substituted, or diluted may avoid detection of drug use
- Urine collected in the early morning is most concentrated and most reliable
- Excessive water intake and diuretic use can lead to diluted urine samples (creatinine <20 mg/dL)
- THC assays are sensitive to adulterants (e.g., Visine eye drops)

Urine Drug Testing (UDT) Federal Work Place Cut Off Values*13-20

Substance	Initial Drug Test Level (immunoassay) (ng/mL)	Confirmatory Drug Test Level (GC–MS) (ng/mL)	Confirmatory Test Analyte	Detection Period After Last Dose**
		Regular UDT		
Amphetamines	500	250	Amphetamine	1–3 days
		250	Methamphetamine	
Cocaine Metabolites	150	100	BEG	1–3 days
Marijuana Metabolites	50	15	THCA	2–8 days single use
				20–30 days chronic use***
Opioid Metabolites	2000***	2000***	Codeine	2–3 days opiates
		2000***	Morphine	3–5 minutes heroin
Phencyclidine (PDP)	25	25	Phencyclidine	Detection time 2–8 days

*Updated Federal Work Place Cut Off Values to start October 2017. **Detection time for most drugs in urine is 1–3 days; ***Long-term use of lipid-soluble drugs (THC, diazepam) can be detected for a longer period of time; ****Testing levels for opiates were raised from 300 ng/mL to 2000 ng/mL to reduce detection from foods containing poppy seeds.

Substance	Initial Drug Test Level (immunoassay) (ng/mL)	Confirmatory Drug Test Level (GC–MS) (ng/mL)	Confirmatory Test Analyte	Detection Period After Last Dose**
		Extended UDT		
Alcohol	N/A	N/A	EtG, EtS	12 hours
6-Monoacetylmorphine (6-MAM) - metabolite of heroin	10	10	6-Monoacetylmorphine (6-MAM)	12–24 hours
Barbiturates	300	200	Butalbital, phenobarbital, secobarbital, amobarbital/ pentobarbital	1 day for short-acting up to 30 days for phenobarbital
Benzodiazepines	300	200	Alprazolam, diazepam, clonazepam, lorazepam, etc.	3 days for short-acting 30 days for long-acting***

*Updated Federal Work Place Cut Off Values to start October 2017. **Detection time for most drugs in urine is 1–3 days; ***Long-term use of lipid-soluble drugs (THC, diazepam) can be detected for a longer period of time; ****Testing levels for opiates were raised from 300 ng/mL to 2000 ng/mL to reduce detection from foods containing poppy seeds.

Substance	Initial Drug Test Level (immunoassay) (ng/mL)	Confirmatory Drug Test Level (GC–MS) (ng/mL)	Confirmatory Test Analyte	Detection Period After Last Dose**
Hydrocodone	300	100	Hydrocodone	2–4 days
Hydromorphone		100	Hydromorphone	
Methadone	300	200	EDDP	3–6 days
Methamphetamine	500	250	Methamphetamine	3–4 days
MDMA		250	MDMA	
MDA		250	MDA	
Oxycodone	100	100	Oxycodone	2–4 days
Oxymorphone		100	Oxymorphone	

*Updated Federal Work Place Cut Off Values to start October 2017. **Detection time for most drugs in urine is 1–3 days; ***Long-term use of lipid-soluble drugs (THC, diazepam) can be detected for a longer period of time; ****Testing levels for opiates were raised from 300 ng/mL to 2000 ng/mL to reduce detection from foods containing poppy seeds.

Summary of Agents Potentially Contributing to False Positives¹³⁻¹⁸

Substance		Agents Potentially Cau	sing False Positives	
Marijuana Metabolites	 dronabinol efavirenzproton	 NSAIDs* proton pump inhibitors 	 hemp foods: tea, oil** THC/CBD topicals 	
Cocaine Metabolites	 coca leaf teas 	topical anesthetics cor	ntaining cocaine	
Opioid Metabolites	 dextromethorphan fluoroquinolones	levofloxacinofloxacin	 poppy seeds poppy oil	rifampinquinine
Amphetamines/ Methamphetamine (High Rate of False Positives)	 amantadine benzphetamine brompheniramine bupropion chlorpromazine desipramine dextroamphetamine 	 doxepin ephedrine fluoxetine isometheptene isoxsuprine labetalol l-methamphetamine (OTC nasal inhaler) 	 methylphenidate MDMA phentermine phenylephrine phenyl- propanolamine promethazine pseudoephedrine 	 ranitidine selegiline thioridazine trazodone trimethobenzamide trimipramine

*NSAIDs resulting in false-positive for marijuana mainly consist of ibuprofen and naproxen and modern tests do not result in false positives; **THC concentrations in hemp products are typically low enough to prevent positive immunoassay results.

Substance		Agents Potentially Causing False Positives
Benzodiazepines	 oxaprozin sertraline	
Barbiturates	ibuprofennaproxen	
Methadone	 chlorpromazine clomipramine diphenhydramine doxylamine 	 ibuprofen quetiapine thioridazine verapamil
Alcohol	mouthwashshort-chain alcohols	OTC cough products(isopropyl alcohol)

*NSAIDs resulting in false-positive for marijuana mainly consist of ibuprofen and naproxen and modern tests do not result in false positives; **THC concentrations in hemp products are typically low enough to prevent positive immunoassay results.

Interpreting Urine Drug Testing^{5,13–15}

Drug or Class	Expected Results	Considerations
Alcohol	Alcohol	 Testing for ETOH metabolites, ethyl glucuronide or ethyl sulfate, can identify alcohol up to 80 hours after consumption
Amphetamines	Immunoassay–amphetamines, methamphetamines or MDMA Confirmatory–amphetamines, methamphetamines or MDMA	 Immunoassay tests are highly cross- reactive; therefore confirmatory testing is required and can identify which amphetamine is present
Benzodiazepines	Immunoassay–unconjugated oxazepam or its metabolites Confirmatory–alprazolam, diazepam, clonazepam, lorazepam, etc.	 Immunoassays for benzodiazepines have a 28% overall false negative rate Confirmatory testing is needed when use is expected or suspected (alprazolam, clonazepam and lorazepam often not detected by immunoassay)
Barbiturates	Confirmatory–butalbital, phenobarbital, secobarbital, amobarbital/pentobarbital	 Presence of a barbiturate in urine at >200 mg/mL indicates use of 1 of these drugs.

Drug or Class	Expected Results	Considerations
Cocaine Metabolites	Immunoassay-cocaine or benzoylecgonine (BEG)	 Cocaine's primary metabolite, BEG, has low cross-reactivity with other substances and is highly predictive of cocaine use A positive result should be interpreted as recent exposure to cocaine
	Opioids or "opiates"- Natural (fro	m opium)
Codeine	Opiates Immunoassay–positive Confirmatory–codeine, possibly morphine and hydrocodone	 Immunoassays for "opiates" are responsive to morphine and codeine but do not identify an individual substance Codeine is metabolized to morphine and small quantities of hydrocodone

Drug or Class	Expected Results	Considerations
	Opioids or "opiates"- Natural (fro	m opium)
Morphine	Opiates Immunoassay–positive Confirmatory–morphine, possibly hydromorphone	 Immunoassays for "opiates" are responsive to morphine and codeine but do not identify an individual substance Morphine (<10%) may be metabolized to hydromorphone
Heroin	Opiates Immunoassay–positive Confirmatory–heroin (6–MAM), morphine, possibly codeine	 6-MAM is pathognomonic for heroin use, detection 12–24 hrs Heroin is metabolized to morphine
Opioid Metabolic Pathways:	CodeineImage: MorphineImage: CodeineImage: MorphineImage: CodeineImage: Codeine	6-MAM ← Heroin Oxycodone ➡ Oxymorphone

Drug or Class	Expected Results	Considerations	
	Opioids-Semisynthetic (derived free	om opium)	
Hydrocodone	Opiates Immunoassay–positive Confirmatory–hydrocodone, possibly hydromorphone	 "Opiates" immunoassay may detect semisynthetic opioids hydrocodone > hydromorphone > 	
Hydromorphone	Opiates Immunoassay-may be positive Confirmatory-hydromorphone	 oxycodone Negative result does not exclude use and confirmatory testing (GCMS or LCMS) is 	
Oxycodone	Opiates Immunoassay–may be positive Oxycodone Immunoassay–positive Confirmatory–oxycodone possibly oxymorphone	 required Hydrocodone is metabolized in small amounts to hydromorphone, both may be found in urine 	
Oxymorphone	Oxycodone Immunoassay–positive Confirmatory–oxymorphone	 Oxycodone is metabolized to oxymorphone, both may be found in urine Hydromorphone and oxymorphone use 	
Buprenorphine	Opiates immunoassay–typically negative Confirmatory–buprenorphine, norbuprenorphine	does not result in positive screens for hydrocodone and oxycodone, respectively	

Drug or Class	Expected Results	Considerations		
	Opioids-Synthetic (man-ma	ide)		
Fentanyl	Opiates immunoassay-negative			
	Fentanyl immunoassay-positive			
	Confirmatory–Fentanyl and norfentanyl	Current "oniates" immunoassays do not		
Meperidine	Opiates immunoassay-negative	detect synthetic opioids		
	Confirmatory-normeperidine, possibly meteridine	Confirmatory testing (GCMS or LCMS) is		
Methadone	Opiates immunoassay-negative	needed		
	Methadone Immunoassay-positive			
	Confirmatory–methadone, EDDP			

Common Adverse Effects for Opioid Analgesics and Suggested Management¹

Adverse Effect	Suggested Management
Pruritus	 Rule out allergic reaction Consider treatment with antihistamine Itching may resolve spontaneously despite continuation of therapy
Sedation	 Rule out other causes Reduce or temporarily hold dose with or without addition of coanalgesic to prevent respiratory depression Add or increase non-sedating adjuvant for additional pain relief
Constipation	 Assess for constipation at every visit Initiate bowel stimulant and a stool softner and increase liquids, dietary fiber (bulk forming laxatives NOT recommended), and exercise If initial regimen is inadequate, mild hyperosmotics, saline and emollient laxatives may be added If possible, reduce or discontinue other drugs that may cause or contribute to constipation

Less Common Adverse Effects¹

Adverse Effect	Signs and Symptoms	Protocol for Management		
Respiratory Depression	Drowsiness; slow shallow, breathing; difficulty staying awake; difficulty awakening; loud or unusual snoring	 Hold opioid completely Avoid other CNS depressants (esp. benzodiazepines) Alert family members/care takers of the signs and symptoms 		
Opioid-induced Endocrinopathy	Loss of libido; impotence; fatigue; mood alterations; loss of muscle mass; abnormal menses; infertility	 Ask patients about symptoms at each visit Determine cause of symptoms (consult endocrinologist) 		
Hallucinations/ DysphoriaConfusion; bad dreams; hallucinations; restlessness; agitation		 Evaluate for underlying cause Eliminate non-essential CNS acting medications (e.g., corticosteroids, anticholinergics) If symptoms persist consider consultation with menta health professional or switch medications 		

Adverse Effect	Signs and Symptoms	Protocol for Management	
Sleep, Disordered Breathing	Loud snoring; irregular pauses in breathing; excessive daytime sleepiness; morning headaches; depression; impaired concentration	 Strongly consider stopping opioid and obtain sleep study Instruct patient to avoid alcohol and medications that cause drowsiness Obstructive sleep apnea: instruct to sleep on side; see dentist about mouthpiece to assist breathing 	
Osteoporosis	Bone fracture	Monitor bone density in patients at risk	
Immune Dysfunction	Severe fatigue; muscle and joint pain that worsens following exertion; decreased immunoglobulins	Obtains labs and consult with immunologist	

Example of Opioid Tapers^{21–26}

Slowest Taper	Slower Taper	Faster Taper	Rapid Taper	
over years	over months or years	over weeks	over days	
Reduce by 2 to 10% every 4 to 8 weeks with pauses in taper as needed.	Reduce by 5 to 20% every 4 weeks with pauses in taper as needed. MOST COMMON TAPER	Reduce by 10 to 20% every week.	Reduce by 20 to 50% of first dose if needed, then reduce by 10 to 20% every day.	

Tips on Tapers

- 1. In most patients, use the slower taper of 5–20% reduction every 4 weeks.
- 2. If Veteran is having withdrawal symptoms using a slower taper, then reduce the speed and follow the slowest taper of 2–10% reduction every 4 to 8 weeks.
- 3. Faster tapers may be necessary in situations where risk of overdose and harm are present.
- 4. Consider hospital admission when rapid tapers are used due to significant withdrawal and risk of patient seeking opioids from alternative sources.
- 5. Communicate the plan clearly to the Veteran, preferably in person, and provide written instructions. Do not mail instructions about tapering without first communicating directly with the patient.

Follow Up with the Veteran During the Taper²⁶

Follow Up	Slowest Taper over years	Slower Taper over months or years	Faster Taper over weeks	Rapid Taper over days	
When	1 to 4 weeks after starting taper then monthly before each reduction.	1 to 4 weeks after starting taper then monthly before each reduction.	Weekly before each dose reduction.	Daily before each dose reduction or if available offer inpatient admission.	
Who	PACT Team*				
How	Clinic and/or telephone**	Clinic and/or telephone**	Clinic and/or telephone**	Hospital, clinic or telephone**	
What	Patient function,*** pain intensity, sleep, physical activity, personal goals, and stress level.				

*Follow up for tapering is recommended to be a team function with various team members taking on roles in which they have demonstrated specific competencies. Mental health practitioners may need to be included in the follow up plan. **Providers will need to determine whether a telephone or in-clinic appointment is appropriate based on the risk category of the Veteran. A Veteran with high risk due to a medical condition may have decompensation during the taper and may require a clinic visit. If there are issues with the Veteran obtaining outside prescriptions or they are displaying other aberrant behaviors during the taper, providing follow up in a clinic visit may be more optimal than a telephone visit. ***Quality of Life Scale for patients with pain: https://www.theacpa.org/uploads/documents/Quality_of_Life_Scale.pdf.

Benzodiazepine Dosage Equivalents and Taper Schedules²⁷

Benzodiazepine	Approx. Dosage Equivalents	Elimination Half-life (hours)	Example Taper: Lorazepam 4 mg bid (Convert to 40 mg diazepam daily)		
Chlordiazepoxide	25 mg	>100 hr	Milestones:	<u>Week 1</u> : 35 mg/day	
Diazepam	10 mg	>100 hr	<u>Week 2</u> : ★ dose by 25%	<u>Week 2</u> : 30 mg/day (25% of	
Clonazepam	1 mg	20–50 hr		Week 3: 25 mg/day	
Lorazepam	2 mg	10–20 hr	Week 4: ★ dose by 25%	Week 4: 20 mg/day (50% of	
Alprazolam	1 mg	12–15 hr	<i>,</i>	initial dose) Weeks 5–8: Continue at 20 mg/day	
Temazepam	15 mg	10–20 hr	<u>Weeks 5–8</u> : Hold dose 1 month <u>Weeks 9–15</u> : ♥ dose by 25% every two weeks	for 1 month <u>Weeks 9–10</u> : 15 mg/day <u>Weeks 11–12</u> : 10 mg/day <u>Weeks 13–14</u> : 5 mg/day <u>Week 15</u> : Discontinue	

Shorter taper (e.g., 3 months): Reduce dose by 50% the first 4 weeks then maintain on that dose for 1–2 months then reduce dose by 5% every 2 weeks.

Longer taper (e.g., 6 months): 10–25% every 4 weeks.

Switching to a longer acting benzodiazepine may be considered if clinically appropriate; in geriatric patients consider tapering the short acting agent until withdrawal symptoms are seen then switch to a longer acting agent; high dose alprazolam may not have complete cross tolerance, and a gradual switch to diazepam or clonazepam before taper may be appropriate; other treatment modalities should be considered (e.g., antidepressants for anxiety) if clinically appropriate.

References

- 1. U.S. Department of Veteran Affairs, Department of Defense. VA/DoD Clinical Practice Guidelines for Opioid Therapy for Chronic Pain. Veterans Health Administration, Office of Quality & Performance, Evidence Review Subgroup; Revised February 2017.
- 2. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. JAMA. April 19, 2016; 315(15):1624–1645.
- 3. Micromedex Drugdex Evaluation. Truven Health Micromedex Solutions. Available at: www.micromedex.com. Accessed March 1, 2017.
- 4. Chou R, Cruciani RA, Fiellin DA, et al. Methadone safety: A clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. *J Pain*. Apr 2014;15(4):321–337.
- 5. Washington State Agency Medical Directors' Group (AMDG). Interagency Guideline on Prescribing Opioids for Pain. 2015 Update. http://www.agencymeddirectors.wa.gov/Files/2015AMDGOpioidGuideline.pdf. Accessed March 2, 2017.
- 6. Evidence-based recommendations for medical management of chronic non-malignant pain. College of Physicians and Surgeons of Ontario; 2000.
- 7. Gebhardt R, Kinney MA. Conversion from intrathecal morphine to oral methadone. *Reg Anesth Pain Med*. May-Jun 2002;27(3):319–321.
- 8. Ripamonti C, De Conno F, Groff L, et al. Equianalgesic dose/ratio between methadone and other opioid agonists in cancer pain: Comparison of two clinical experiences. *Ann Oncol.* Jan 1998;9(1):79–83.
- 9. Weschules DJ, Bain KT. A systematic review of opioid conversion ratios used with methadone for the treatment of pain. *Pain Med.* Jul-Aug 2008;9(5):595–612.

continued

- 10. Bruera E, Neumann CM. Role of methadone in the management of pain in cancer patients. *Oncology (Williston Park)*. Sep 1999;13(9):1275–1282; discussion 1285–1278, 1291.
- 11. Walker PW, Palla S, Pei BL, et al. Switching from methadone to a different opioid: What is the equianalgesic dose ratio? *J Palliat Med*. Oct 2008;11(8):1103–1108.
- 12. Krebs EE, Lorenz KA, Bair, MJ, et. al. Development and initial validation of the PEG, a three-item scale assessing pain intensity and interference. *J Gen Intern Med* 2009 June;24(6):733–738.
- 13. Standridge JB, Adams SM, Zotos AP. Urine drug screening: A valuable office procedure. *Am Fam Physician*. Mar 1 2010;81(5):635–640.
- 14. Moeller KE, Lee KC, Kissack JC. Urine drug screening: Practical guide for clinicians. Mayo Clin Proc. Jan 2008;83(1):66–76.
- Gourlay DL, Heit HA, Caplan YH. Urine Drug Testing in Clinical Practice. 5th ed. Conneticut: PharmaCom Group, Inc. Urine drug testing in clinical practice. 5th ed. 2012; http://eo2.commpartners.com/users/ama/downloads/udt5_Copy.pdf.
- 16. Vincent EC, Zebelman A, Goodwin C, Stephens MM. Clinical inquiries. What common substances can cause false positives on urine screens for drugs of abuse? *J Fam Pract*. Oct 2006;55(10):893–894, 897.
- 17. Woelfel J. Drug abuse urine tests: False-positive results. Pharmacist's Letter/Prescriber's Letter. 2005;21(3):210314.
- 18. Brahm NC, Yeager LL, Fox MD, Farmer KC, Palmer TA. Commonly prescribed medications and potential false-positive urine drug screens. *Am J Health Syst Pharm*. Aug 15 2010;67(16):1344–1350.
- 19. Verstraete AG. Detection times of drugs of abuse in blood, urine, and oral fluid. Ther Drug Monit. Apr 2004;26(2):200–205.
- 20. Substance Abuse and Mental Health Services Administration (SAMHSA). Revised Mandatory Guidelines by the Secretary of Health and Human Services. January 23, 2017. Effective date: October 1, 2017. https://www.federalregister.gov/ documents/2017/01/23/2017-00979/mandatory-guidelines-for-federal-workplace-drug-testing-programs.

- 21. US Department of Veterans Affairs. VA PBM Academic Detailing Service. Opioid Taper Decision Tool 2016. http://www.pbm. va.gov/PBM/AcademicDetailingService/Documents/Pain_Opioid_Taper_Tool_IB_10_939_P96820.pdf. Accessed March 1, 2017.
- Canadian Guideline for Safe and Effective Use of Opioids for Chronic Non-Cancer Pain Part B: Recommendations for Practice, Version 5.5. April 30, 2010. [NOUGG] Accessed at: http://nationalpaincentre.mcmaster.ca/documents/opioid_ guideline_part_b_v5_6.pdf.
- 23. Berna C, Kulich RJ, Rathmell JP. Tapering Long-term Opioid Therapy in Chronic Noncancer Pain: Evidence and Recommendations for Everyday Practice. *Mayo Clin Proc.* 2015:90(6):828–842.
- 24. Kral, LA; Jackson K, Uritsky TJ. A practical guide to tapering opioids. Ment Health Clin (internet). 2015;5(3):102–108. DOI: 10.9740/mhc.2015.05.102.
- 25. Chou R, Fanciullo GJ, Fine PG, Adler JA, et al. Clinical guidelines for the use of chronic opioid therapy in chronic non-cancer pain. *J Pain*. 2009;10(2):113–30. DOI: 10.1016/j.jpain.2008.10.008.
- Kahan M, Wilson L, Mailis-Gagnon A, Srivastava A, National Opioid Use Guideline G. Canadian guideline for safe and effective use of opioids for chronic non-cancer pain: clinical summary for family physicians. Part 2: special populations. *Can Fam Physician*. 2011;57(11):1269–76, e419–28.
- 27. US Department of Veterans Affairs. VA PBM Academic Detailing Service. Benzodiazepine Risk Discussion Guide. http://www. pbm.va.gov/PBM/AcademicDetailingService/Documents/Benzodiazepine_Provider_AD_%20Risk_Discussion_ Guide.pdf. Accessed March 1, 2017.

Notes			

U.S. Department of Veterans Affairs

This reference guide was created to be used as a tool for VA providers and is available to use from the Academic Detailing SharePoint. These are general recommendations only; specific clinical decisions should be made by the treating provider based on an individual patient's clinical condition.

VA PBM Academic Detailing Service Email Group PharmacyAcademicDetailingProgram@va.gov

VA PBM Academic Detailing Service SharePoint Site https://vaww.portal2.va.gov/sites/ad/SitePages/Home.aspx

VA PBM Academic Detailing Public Website http://www.pbm.va.gov/PBM/academicdetailingservicehome.asp



July 2017

IB 10-999, P96865